Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary
EQS-News: Biotest AG / Key word(s): Miscellaneous
Biotest AG opens 12th plasma collection centre in Hungary
In the future, plasma donors will be able to donate plasma six days a week, from Monday to Saturday, at the state-of-the-art centre in Budapest's Kelenföld district. The centre is located in the southern part of Buda and is one of the most modern in Europe The first plasmapheresis station of Plazmaszolgálat Kft, a 100% subsidiary of Biotest AG, was opened over ten years ago.
"With our fourth centre in Budapest, we are creating 19 new, highly qualified jobs. Our great thanks go to the future donors and their commitment to the care of patients in Hungary and worldwide," emphasises Barnabás Bolla, Chief Operating Officer Plazmaszolgálat Kft.
Biotest is thus continuing the planned expansion of its own donor centres in Europe in order to secure the supply of patients in the long term.
"Within a short period of time, our dedicated team in Hungary has created all the conditions to continue the successful development of the last few years. We hope that we will soon be able to welcome a large number of donors," emphasises Henrik Oehme, Managing Director of Plasma Service Europe GmbH.
The collected plasma is processed exclusively at Biotest AG in Dreieich in Germany. Audits conducted regularly in Hungary ensure that the high legal and internal quality requirements are met. The finished medicinal products made from plasma are distributed by Biotest in Hungary via the Hungarian subsidiary Biotest Hungaria Kft.
About human blood plasma
Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups. Biotest is one of the world's six largest manufacturers of plasma protein products.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,300 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest is part of the Grifols Group, Barcelona, Spain (www.grifols.com).
Dr Monika Buttkereit
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1615509|
|End of News||EQS News Service|